CL2018000726A1 - Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1 - Google Patents
Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1Info
- Publication number
- CL2018000726A1 CL2018000726A1 CL2018000726A CL2018000726A CL2018000726A1 CL 2018000726 A1 CL2018000726 A1 CL 2018000726A1 CL 2018000726 A CL2018000726 A CL 2018000726A CL 2018000726 A CL2018000726 A CL 2018000726A CL 2018000726 A1 CL2018000726 A1 CL 2018000726A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- syd985
- cancer patients
- conjugate
- patients resistant
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229960001612 trastuzumab emtansine Drugs 0.000 abstract 3
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 abstract 2
- 239000000611 antibody drug conjugate Substances 0.000 abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- RFQYSAASDBNNDZ-UCGHAGIGSA-N [(1s)-1-(chloromethyl)-3-[6-[(4-hydroxybenzoyl)amino]imidazo[1,2-a]pyridine-2-carbonyl]-9-methyl-1,2-dihydrobenzo[e]indol-5-yl] n-[2-[[4-[[(2s)-5-(carbamoylamino)-2-[[(2s)-2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxycarbonylamino]-3-methylbutanoyl]amino]pe Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(COC(=O)N(C)CCN(CCOCCO)C(=O)OC=2C3=CC=CC(C)=C3C=3[C@H](CCl)CN(C=3C=2)C(=O)C=2N=C3C=CC(NC(=O)C=4C=CC(O)=CC=4)=CN3C=2)=CC=1)C(=O)OCCOCCN1C(=O)C=CC1=O RFQYSAASDBNNDZ-UCGHAGIGSA-N 0.000 abstract 1
- 229960005501 duocarmycin Drugs 0.000 abstract 1
- VQNATVDKACXKTF-XELLLNAOSA-N duocarmycin Chemical compound COC1=C(OC)C(OC)=C2NC(C(=O)N3C4=CC(=O)C5=C([C@@]64C[C@@H]6C3)C=C(N5)C(=O)OC)=CC2=C1 VQNATVDKACXKTF-XELLLNAOSA-N 0.000 abstract 1
- 229930184221 duocarmycin Natural products 0.000 abstract 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 abstract 1
- 229960000575 trastuzumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
<p>La presente invención se relaciona con el conjugado de anticuerpo-fármaco (ADC) que contienen duocarmicina trastuzumab vc-seco-DUBA (SYD985) para el tratamiento de pacientes con cáncer HER2 IHC 3+ o HER2 IHC 2+/FISH positivo resistente al tratamiento con trastuzumab emtansina (T-DM1), específicamente pacientes con cáncer mamario resistente al tratamiento con T-DM1.</p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15186258 | 2015-09-22 | ||
| EP16158710 | 2016-03-04 | ||
| EP16169699 | 2016-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000726A1 true CL2018000726A1 (es) | 2018-06-01 |
Family
ID=57068063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000726A CL2018000726A1 (es) | 2015-09-22 | 2018-03-20 | Tratamiento con conjugado syd985 de pacientes con cáncer resistente al tratamiento con t-dm1 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10821191B2 (es) |
| EP (1) | EP3352857B1 (es) |
| JP (1) | JP6591665B2 (es) |
| KR (1) | KR20180052761A (es) |
| CN (1) | CN108025190A (es) |
| AU (1) | AU2016328461B2 (es) |
| BR (1) | BR112018005494A2 (es) |
| CA (1) | CA2996600A1 (es) |
| CL (1) | CL2018000726A1 (es) |
| CY (1) | CY1123818T1 (es) |
| DK (1) | DK3352857T3 (es) |
| ES (1) | ES2854298T3 (es) |
| HR (1) | HRP20210418T1 (es) |
| HU (1) | HUE053614T2 (es) |
| LT (1) | LT3352857T (es) |
| MX (1) | MX386402B (es) |
| MY (1) | MY194488A (es) |
| PL (1) | PL3352857T3 (es) |
| RU (1) | RU2728101C2 (es) |
| WO (1) | WO2017050846A1 (es) |
| ZA (1) | ZA201801022B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005484A (es) * | 2018-11-09 | 2021-06-18 | Byondis Bv | Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados. |
| CA3165135A1 (en) * | 2019-12-20 | 2021-06-24 | Pfizer Inc. | Treatment with site specific her2 antibody-drug conjugates |
| US20240424103A1 (en) * | 2021-10-20 | 2024-12-26 | National Institute Of Advanced Industrial Science And Technology | Anticancer agent, prodrug of anticancer agent, method for killing cancer cell in vitro, cancer treatement method, and cancer treatment device |
| PL445704A1 (pl) * | 2023-07-28 | 2025-02-03 | Instytut Chemii i Techniki Jądrowej | Koniugat trastuzumab-emtanzyna znakowany izotopowo o właściwościach przeciwnowotworowych, sposób jego otrzymywania i jego zastosowanie w terapii antynowotworowej |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5606916B2 (ja) * | 2007-10-19 | 2014-10-15 | ジェネンテック， インコーポレイテッド | システイン操作抗ｔｅｎｂ２抗体および抗体薬物結合体 |
| NO3056203T3 (es) * | 2010-04-21 | 2018-05-12 | ||
| ES2668984T3 (es) | 2014-01-10 | 2018-05-23 | Synthon Biopharmaceuticals B.V. | CAF de duocarmicina para su uso en el tratamiento del cáncer de vejiga |
-
2016
- 2016-09-21 LT LTEP16775553.7T patent/LT3352857T/lt unknown
- 2016-09-21 DK DK16775553.7T patent/DK3352857T3/da active
- 2016-09-21 ES ES16775553T patent/ES2854298T3/es active Active
- 2016-09-21 CN CN201680054664.3A patent/CN108025190A/zh active Pending
- 2016-09-21 CA CA2996600A patent/CA2996600A1/en active Pending
- 2016-09-21 HR HRP20210418TT patent/HRP20210418T1/hr unknown
- 2016-09-21 JP JP2018515142A patent/JP6591665B2/ja not_active Expired - Fee Related
- 2016-09-21 KR KR1020187010953A patent/KR20180052761A/ko not_active Abandoned
- 2016-09-21 BR BR112018005494A patent/BR112018005494A2/pt not_active Application Discontinuation
- 2016-09-21 MX MX2018003459A patent/MX386402B/es unknown
- 2016-09-21 EP EP16775553.7A patent/EP3352857B1/en active Active
- 2016-09-21 PL PL16775553T patent/PL3352857T3/pl unknown
- 2016-09-21 AU AU2016328461A patent/AU2016328461B2/en not_active Ceased
- 2016-09-21 RU RU2018114457A patent/RU2728101C2/ru active
- 2016-09-21 MY MYPI2018000414A patent/MY194488A/en unknown
- 2016-09-21 HU HUE16775553A patent/HUE053614T2/hu unknown
- 2016-09-21 US US15/762,171 patent/US10821191B2/en not_active Expired - Fee Related
- 2016-09-21 WO PCT/EP2016/072464 patent/WO2017050846A1/en not_active Ceased
-
2018
- 2018-02-14 ZA ZA2018/01022A patent/ZA201801022B/en unknown
- 2018-03-20 CL CL2018000726A patent/CL2018000726A1/es unknown
-
2021
- 2021-02-16 CY CY20211100128T patent/CY1123818T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016328461A1 (en) | 2018-02-22 |
| HRP20210418T1 (hr) | 2021-04-30 |
| RU2018114457A (ru) | 2019-10-24 |
| LT3352857T (lt) | 2021-02-25 |
| JP2018527402A (ja) | 2018-09-20 |
| ES2854298T3 (es) | 2021-09-21 |
| US20180280533A1 (en) | 2018-10-04 |
| CY1123818T1 (el) | 2022-05-27 |
| MX2018003459A (es) | 2018-06-06 |
| RU2728101C2 (ru) | 2020-07-28 |
| WO2017050846A1 (en) | 2017-03-30 |
| US10821191B2 (en) | 2020-11-03 |
| DK3352857T3 (da) | 2021-03-01 |
| MY194488A (en) | 2022-11-30 |
| MX386402B (es) | 2025-03-18 |
| JP6591665B2 (ja) | 2019-10-16 |
| EP3352857A1 (en) | 2018-08-01 |
| CN108025190A (zh) | 2018-05-11 |
| RU2018114457A3 (es) | 2020-01-31 |
| ZA201801022B (en) | 2021-05-26 |
| HUE053614T2 (hu) | 2021-07-28 |
| KR20180052761A (ko) | 2018-05-18 |
| AU2016328461B2 (en) | 2021-04-08 |
| CA2996600A1 (en) | 2017-03-30 |
| PL3352857T3 (pl) | 2021-08-02 |
| EP3352857B1 (en) | 2021-01-13 |
| BR112018005494A2 (pt) | 2018-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023014569A (es) | Anticuerpos anti-sirpa. | |
| ZA201906111B (en) | Cyclic di-nucleotides compounds for the treatment of cancer | |
| ZA201906832B (en) | Novel psma-binding agents and uses thereof | |
| CY1123983T1 (el) | Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου | |
| MX2023014093A (es) | Compuestos que interactuan con glicano y metodos de uso. | |
| CL2019000221A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1. | |
| CL2018001512A1 (es) | Anticuerpos anti-cd73 humanizados. | |
| NZ752526A (en) | Pyrrolobenzodiazepine conjugates | |
| CL2018000292A1 (es) | Compuestos farmacéuticos | |
| MX2016007825A (es) | Compuestos peptidomimeticos y conjugados de anticuerpo-farmaco de los mismos. | |
| GEP20217281B (en) | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| EA201692100A8 (ru) | Новые антитела против rnf43 и способы их применения | |
| SA519410320B1 (ar) | مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل | |
| MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
| CY1123818T1 (el) | Syd985 θεραπεια δυσιατων me t-dm1 ασθενων με καρκινο | |
| EA201890221A1 (ru) | Hbed-бисфосфонаты, их конъюгаты с радиометаллом и их применение в качестве лечебно-диагностических агентов | |
| EA202191175A1 (ru) | Сконструированные с цистеином конъюгаты антитело-лекарственное средство, содержащие пептидсодержащие линкеры | |
| EA201991196A1 (ru) | Претерпевшие самосборку диблок-сополимеры, состоящие из pegmema и несущих лекарственное средство полимерных сегментов | |
| SG11202011243XA (en) | Treatment of her2-mutated cancer by administering anti-her2 antibody-drug conjugate | |
| EA201891527A1 (ru) | Композиции и способы обнаружения и лечения рака пищевода | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. |